In a patient with suspected acute hereditary angioedema flare (maternal history, swollen lips) and severe pain (10/10), should quantitative C4 and C1‑inhibitor antigen and functional assays be drawn before any medication, and what immediate IV analgesia and airway monitoring are recommended?

Immediate Management of Suspected Acute HAE

Draw C4 and C1-inhibitor levels (both antigen and functional) immediately before any medications, provide IV narcotic analgesia for the severe pain, and ensure continuous airway monitoring with intubation capability readily available while arranging for HAE-specific therapy (C1-INH concentrate, icatibant, or ecallantide). 1

Diagnostic Testing Priority

Obtain labs now, but do not delay treatment:

• C4 level is the critical screening test—virtually 100% of HAE patients have low C4 during acute attacks 1
• C1-INH antigen and functional levels distinguish type I (low antigen) from type II (normal antigen, low function) 1
• These tests confirm diagnosis but should not delay HAE-specific treatment when clinical suspicion is high (maternal history, facial/lip swelling, no urticaria) 1

Important caveat: Samples must reach the lab promptly—C4 and C1-INH function degrade ex vivo, causing falsely low results if delayed 1

Immediate Symptomatic Management

Pain Control

Administer IV narcotic analgesia immediately for the 10/10 pain 1. The guidelines explicitly state:

• Patients with HAE attacks "often require narcotic medications for control of the pain" 1
• This is symptomatic treatment while arranging HAE-specific therapy
• Avoid potent long-acting narcotics (fentanyl patches, oxycodone) for outpatient use due to addiction risk with recurrent attacks 1

Critical Airway Monitoring

This patient requires observation in a facility capable of emergency intubation or tracheostomy 1. With facial/lip involvement:

• Monitor continuously for voice changes, inability to swallow, or breathing difficulty—these signal impending airway closure 1
• Over 50% of HAE patients experience at least one laryngeal attack in their lifetime, which can be fatal 1
• Laryngeal attacks are life-threatening and associated with significant mortality 1

HAE-Specific Treatment

The physician must arrange for one of three FDA-approved HAE-specific agents 1:

1. Plasma-derived C1-INH concentrate (preferred)
2. Icatibant (bradykinin B2 receptor antagonist)
3. Ecallantide (plasma kallikrein inhibitor)

All three have demonstrated efficacy and safety in randomized controlled trials 1. Early administration is most effective—treatment should begin as soon as possible in an attack 1.

What NOT to Use

Epinephrine, corticosteroids, and antihistamines are NOT efficacious and NOT recommended for HAE treatment 1. These standard angioedema treatments do not work because HAE is bradykinin-mediated, not histamine-mediated 1.

Fresh frozen plasma can be used if HAE-specific agents are unavailable, but carries risk of viral transmission and can occasionally acutely worsen symptoms 1.

Clinical Reasoning

This presentation is highly suggestive of HAE:

• Maternal family history (autosomal dominant inheritance) 1
• Facial/lip swelling (characteristic distribution) 1
• Severe pain (typical of HAE attacks, especially with potential oropharyngeal involvement) 1

The typical HAE attack pattern: progressive worsening over 24 hours, peaks, then slowly resolves over 48-72 hours 1. This patient appears early in that progression, making immediate intervention critical to prevent airway compromise.

Key Pitfalls to Avoid

1. Do not wait for lab confirmation to initiate HAE-specific treatment when clinical suspicion is high and airway is threatened 1
2. Do not waste time with antihistamines/steroids/epinephrine—they don't work in HAE 1
3. Do not underestimate airway risk—facial swelling can progress to laryngeal edema 1
4. Do not send the patient home until swelling stabilizes and airway safety is assured 1